생체역동학 모델을 이용한 감마선 방출 핵종의 유효반감기 계산
Calculation of Effective Half-life of Gamma Emission Radionuclide using Bio-kinetic Model
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Patients administered radioisotope for medical purposes are regulated by each country to quarantine them until their body’s radioactivity contents decrease below release criteria. To predict the quarantine period and provide it to medical staffs and patients, it is necessary to approach the assessment of the exposure dose of persons due to patients in a realistic manner. For this purpose, a whole-body effective half-life should be applied to the dose assessment equation instead of the physical half-life. In this study, we constructed a bio-kinetic model for each nuclear species based on the ICRP publication to obtain a whole-body effective half-life of 10 unsealed gamma-ray emitting nuclei from the notification of Nuclear Safety and Security Commission, and calculated the effective half-life mathematically by simulating the distribution of the radioisotope administered in the whole body as well as each organ scale. The whole-body effective half-life of 198Au, 67Ga, 123I, 111In, 186Re, 99mTc, and 201Tl were 1,93, 2.57, 0.295, 2.805, 1.561, 0.245, and 2.397 days respectively. However, it was found to be undesirable to offer a single value of the effective half-life of 125I, 131I, and 169Yb because the changes in the effective half-life show no linearity. A bio-kinetic model created for the internal exposure assessment has been shown to be possible to calculate the effective half-life of radioisotopes administered in the patient’s body, but subsequent studies of radio- labeled compounds are required as well.
Abstract
Patients administered radioisotope for medical purposes are regulated by each country to quarantine them until their body’s radioactivity contents decrease below release criteria. To predict the quarantine period and provide it to medical staffs and patients, it is necessary to approach the assessment of the exposure dose of persons due to patients in a realistic manner. For this purpose, a whole-body effective half-life should be applied to the dose assessment equation instead of the physical half-life. In this study, we constructed a bio-kinetic model for each nuclear species based on the ICRP publication to obtain a whole-body effective half-life of 10 unsealed gamma-ray emitting nuclei from the notification of Nuclear Safety and Security Commission, and calculated the effective half-life mathematically by simulating the distribution of the radioisotope administered in the whole body as well as each organ scale. The whole-body effective half-life of 198Au, 67Ga, 123I, 111In, 186Re, 99mTc, and 201Tl were 1,93, 2.57, 0.295, 2.805, 1.561, 0.245, and 2.397 days respectively. However, it was found to be undesirable to offer a single value of the effective half-life of 125I, 131I, and 169Yb because the changes in the effective half-life show no linearity. A bio-kinetic model created for the internal exposure assessment has been shown to be possible to calculate the effective half-life of radioisotopes administered in the patient’s body, but subsequent studies of radio- labeled compounds are required as well.
참고문헌 (23)
- 이상경, "비밀봉 방사성동위원소 투여환자의 전신유효반감기와 환자선량률계수 계산", 대한방사선과학회 춘계학술대회 (2017)
- Atkins HL, "Thallium-201 for medical use. Part 3: Human distribution and physical imaging properties", J. Nucl. Med, 18, pp.133~140 (1977)
- Durbin PW., "The distribution of radioisotopes of some heavy metal in the rat", Univ. Calif. Publ. Pharmacol, 3, pp.1~34 (1957)
- Howe B, "NUREG-1556:Consolidated guidance about materials licenses", U.S.NRC, ~ (2008)
- Report of committee II on permissible dose for internal radiation, "ICRP", Pergamon Press, ~, pp.ICRP publication 2 (1959)
- Report of committee IV on evaluation of radiation doses to body tissues from internal contamination due to occupational exposure, "ICRP", Pergamon Press, ~, pp.ICRP publication 10 (1968)
- ICRP, "Limits for intakes of radionuclides by workers. ICRP publication 30 Part 1", Pergamon Press, ~ (1979)
- ICRP, "Limits for intakes of radionuclides by workers. ICRP publication 30 Part 2", Pergamon Press, ~ (1980)
- ICRP, "Limits for intakes of radionuclides by workers. ICRP publication 30 Part 3", Pergamon Press, ~ (1981), Pergamon Press
- ICRP, "Age-dependent doses to members of the public from intake of radionuclides: Part 1", ICRP publication 56. Pergamon Press, ~ (1990)
- ICRP, "Age-dependent doses to members of the public from intake of radionuclides: Part 2", ICRP publication 67. Pergamon Press, ~ (1993)
- ICRP, "Dose coefficients for intakes of radionuclides by workers", ICRP publication 68. Pergamon Press, ~ (1994)
- ICRP, "Individual monitoring for internal exposure of workers", ICRP publication 78. Pergamon Press, ~ (1997)
- 김성철, "갑상선암 환자에서 고용량 방사성요오드 치료 후 유효반감기에 대한 연구", 한국방사선학회논문지, 11(7), pp.597~603 (2017), 한국방사선학회[DOI]
- Kobe C, "Radioiodine therapy of benign thyroid disorders: what are the deective thyroidal half-life and uptake of 131I", Nucl. Med. Commun, 31, pp.201~205 (2010)
- Mascarenhas BR, "Gold metabolism in patients with rheumatoid arthritis treated with gold compounds-reinvestigated", Arthritis. Rheum, 15(4), pp.391~402 (1972)
- North DL, "Effective half-hife of 131I in thyroid cancer patients", Health Phys, 81(3), pp.325~329 (2001)
- 박석건, "I-131 치료를 받은 분화갑상선암 환자에서 I-131의 유효반감기", Nuclear Medicine and Molecular Imaging, 42(6), pp.464~468 (2008), 대한핵의학회
- Remy H, "131I effective half-life and dosimetry in thyroid cancer patients", Korean J. Nucl. Med, 49(9), pp.1445~1450 (2008)
- Sharma A, "Estimation of effective half-hife of I-131 in differentiated thyroid cancer patients in a tertiary care hospital in India: a retrospective study", JMSCR, 5(3), pp.18740~11846 (2017)
- So YS, "Measurements of actual effective half-life in 131I therapy for Graves’ hyperthyroidism", Korean J. Nucl. Med, 30(1), pp.77~85 (1996)
- Willegaignon J, "131I effective half-hife (Teff) for patients with thyroid cancer", Health Physics, 91(2), pp.119~122 (2006)
- Zhang R, "Prediction of thyroidal 131I effective half-life in patients with Graves’ disease", Oncotarget, 8(46), pp.80934~80940 (2017)